Patients' understanding of oncology clinical endpoints: A literature review.

[1]  L. Amiri-Kordestani,et al.  Patient‐Friendly Language to Facilitate Treatment Choice for Patients with Cancer , 2019, The oncologist.

[2]  E. Eisenhauer,et al.  Imaging progression-free survival: How much does it matter to patients? , 2018, Journal of Clinical Oncology.

[3]  L. Howie,et al.  A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review , 2018, JAMA oncology.

[4]  S. Gore,et al.  Prognostic understanding in acute leukemia: Patient-physician differences. , 2018 .

[5]  L. Fallowfield,et al.  Do drugs offering only PFS maintain quality of life sufficiently from a patient’s perspective? Results from AVALPROFS (Assessing the ‘VALue’ to patients of PROgression Free Survival) study , 2018, Supportive Care in Cancer.

[6]  Amie C O'Donoghue,et al.  Awareness of misinformation in health-related advertising: A narrative review of the literature , 2018 .

[7]  E. Low,et al.  Individual Trade‐Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma , 2017, The oncologist.

[8]  M. Halpern,et al.  Patient experiences of cancer care: scoping review, future directions, and introduction of a new data resource: Surveillance Epidemiology and End Results-Consumer Assessment of Healthcare Providers and Systems (SEER-CAHPS) , 2017 .

[9]  P. Viens,et al.  Marketing Authorization Procedures for Advanced Cancer Drugs: Exploring the Views of Patients, Oncologists, Healthcare Decision Makers, and Citizens in France , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  V. Prasad,et al.  Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. , 2016, Mayo Clinic proceedings.

[11]  Adam P Dicker,et al.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  W. Greiner,et al.  Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies? , 2015, BioMed research international.

[13]  E. Saad,et al.  Treatment priorities in oncology: do we want to live longer or better? , 2014, Clinics.

[14]  S. Gray,et al.  Class, race and ethnicity and information avoidance among cancer survivors , 2013, British Journal of Cancer.

[15]  John F P Bridges,et al.  Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. , 2012, Lung cancer.

[16]  J. Temel,et al.  Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Nancy D Berkman,et al.  Health Literacy: What Is It? , 2010, Journal of health communication.

[18]  S. Gandhi,et al.  63 A comparison of physician and patient perceptions of clinically important endpoints in the treatment of Metastatic Breast Cancer (MBC) , 2010 .

[19]  Richard L. Street,et al.  Patient-centered communication in cancer care: Promoting healing and reducing suffering , 2007 .

[20]  Thomas J. Smith,et al.  Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Craft,et al.  Knowledge of treatment intent among patients with advanced cancer: a longitudinal study. , 2005, European journal of cancer care.

[22]  L. Fallowfield,et al.  Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits , 2016, Supportive Care in Cancer.